Ignyta's entrectinib leads to durable responses in NSCLC population

Ignyta Inc. (NASDAQ:RXDX) climbed $1.90 (13%) to $16.25 on Wednesday after reporting interim data from the Phase II STARTRK-2 basket study of entrectinib (RXDX-101) to treat non-small cell lung cancer.

Among patients with c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) fusion-positive, locally advanced or metastatic NSCLC, entrectinib led to an overall response rate (ORR) of 78% (95% CI: 60.0, 90.7), as measured by investigator assessment, and 69% (95% CI: 50.0, 83.9) as measured by blinded independent central review...